WO2017105212A3 - Matrices covalientes biodegradables para el suministro de insulina por vía oral dirigida al colon activado por la microbiota y proceso para su obtención - Google Patents

Matrices covalientes biodegradables para el suministro de insulina por vía oral dirigida al colon activado por la microbiota y proceso para su obtención Download PDF

Info

Publication number
WO2017105212A3
WO2017105212A3 PCT/MX2016/000170 MX2016000170W WO2017105212A3 WO 2017105212 A3 WO2017105212 A3 WO 2017105212A3 MX 2016000170 W MX2016000170 W MX 2016000170W WO 2017105212 A3 WO2017105212 A3 WO 2017105212A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
colon
directed
microbiota
activated
Prior art date
Application number
PCT/MX2016/000170
Other languages
English (en)
French (fr)
Other versions
WO2017105212A2 (es
Inventor
Ana Luisa MARTÍNEZ-LÓPEZ
Elizabeth CARVAJAL-MILLÁN
Norberto SOTELO-CRUZ
Valerie MICARD
Agustín RASCÓN CHU
Satya Prakash
Jaime LIZARDI-MENDOZA
Yolanda Leticia LÓPEZ-FRANCO
Rafael CANETT-ROMERO
Alma Rosa TOLEDO-GUILLÉN
Original Assignee
Centro De Investigación En Alimentación Y Desarrollo, A.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investigación En Alimentación Y Desarrollo, A.C. filed Critical Centro De Investigación En Alimentación Y Desarrollo, A.C.
Priority to CN201680082119.5A priority Critical patent/CN108778258B/zh
Priority to EP16876109.6A priority patent/EP3666264B1/en
Publication of WO2017105212A2 publication Critical patent/WO2017105212A2/es
Publication of WO2017105212A3 publication Critical patent/WO2017105212A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe un biomaterial covalente formado con arabinoxilanos ferulados gelificantes los cuales son biodegradables y permite la administración de insulina por vía oral dirigida al colon. La presente invención también incluye un método para la preparación de partículas reticuladas covalentemente vía enzimática. Esta composición farmacéutica es especialmente útil en la industria biomédica o farmacéutica como tratamiento no invasivo para la administración oral de insulina o análogos de insulina en pacientes con Diabetes tipo I.
PCT/MX2016/000170 2015-12-18 2016-12-19 Matrices covalientes biodegradables para el suministro de insulina por vía oral dirigida al colon activado por la microbiota y proceso para su obtención WO2017105212A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201680082119.5A CN108778258B (zh) 2015-12-18 2016-12-19 用于提供靶向结肠的口服胰岛素的被微生物群激活的生物可降解共价基质和获得这些基质的方法
EP16876109.6A EP3666264B1 (en) 2015-12-18 2016-12-19 Biodegradable covalent matrices for the oral delivery of insulin directed to the colon, activated by microbiota, and production method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXMX/A/2015/017857 2015-12-18
MX2015017857A MX2015017857A (es) 2015-12-18 2015-12-18 Matrices covalentes biodegradables para el suministro de insulina por via oral dirigida al colon activado por la microbiota y proceso para su obtencion.

Publications (2)

Publication Number Publication Date
WO2017105212A2 WO2017105212A2 (es) 2017-06-22
WO2017105212A3 true WO2017105212A3 (es) 2017-11-09

Family

ID=59056981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2016/000170 WO2017105212A2 (es) 2015-12-18 2016-12-19 Matrices covalientes biodegradables para el suministro de insulina por vía oral dirigida al colon activado por la microbiota y proceso para su obtención

Country Status (4)

Country Link
EP (1) EP3666264B1 (es)
CN (1) CN108778258B (es)
MX (1) MX2015017857A (es)
WO (1) WO2017105212A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109528683A (zh) * 2018-12-13 2019-03-29 浙江华康药业股份有限公司 一种阿拉伯糖定点释放对肠内产丁酸菌的调控方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049320A2 (en) * 2000-01-05 2001-07-12 Cambridge Biopolymers Limited Use of hemicellulose microparticles as vaccine adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution
CN104004231A (zh) * 2014-06-12 2014-08-27 东南大学 一种生物大分子互穿网络水凝胶及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049320A2 (en) * 2000-01-05 2001-07-12 Cambridge Biopolymers Limited Use of hemicellulose microparticles as vaccine adjuvant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERLANGA-REYES, CLAUDIA M. ET AL.: "Maize arabinoxilan gels as protein delivery matrices", MOLECULES, vol. 14, no. 4, 8 April 2009 (2009-04-08), pages 1475 - 1482, XP055437409, Retrieved from the Internet <URL:www.mdpi.com/journal/molecules> [retrieved on 20171207] *
GUEVARA-BRETON, N. A. ET AL.: "encapsulación: técnicas and aplicaciones in the industria alimentaria", TEMAS SELECTOS OF INGENIERÍA OF ALIMENTOS, vol. 2, 2008, pages 36 - 49, XP055437412, [retrieved on 20171207] *
KUMAR VIKAS ET AL.: "Dietary Roles of Non-Starch Polysachharides in Human Nutrition: A Review", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, vol. 52, no. 10, October 2011 (2011-10-01), pages 899 - 935, XP055437415, ISSN: 1040-8398 *
MOZHAEV, VADIM V. ET AL.: "Catalytic activity and denaturation of enzymes in waterlorganic cosolvent mixtures", EUR. J. BIOCHEM., vol. 184, February 1989 (1989-02-01), pages 597 - 602, XP055437419 *
NINO-MEDINA GUILLERMO ET AL.: "Feruloylated arabinoxylans and arabinoxylan gels: structure, sources and applications", PHYTOCHEMISTRY REVIEWS MAR 2010, vol. 9, no. 1, 28 February 2010 (2010-02-28), pages 111 - 120, XP019794059, ISSN: 1568-7767 *

Also Published As

Publication number Publication date
CN108778258A (zh) 2018-11-09
MX2015017857A (es) 2017-06-29
CN108778258B (zh) 2023-02-28
EP3666264A2 (en) 2020-06-17
EP3666264A4 (en) 2021-03-24
EP3666264C0 (en) 2023-06-07
EP3666264B1 (en) 2023-06-07
WO2017105212A2 (es) 2017-06-22

Similar Documents

Publication Publication Date Title
MX2023006541A (es) Formulaciones de dosis fija.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
NZ741291A (en) Stabilizing camptothecin pharmaceutical compositions
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
EP4218823A3 (en) Novel polymeric hgh prodrugs
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
WO2008119457A3 (de) Lactam-substituierte dicarbonsäuren und ihre verwendung
MX2015011121A (es) Recubrimiento biocompatible tipo multicapa-pelicula delgada como tratamiento superficial de sustratos biomedicos y proceso de fabricacion del mismo.
MX364680B (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
WO2016040814A3 (en) Disulfide polymers and methods of use
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2017105212A3 (es) Matrices covalientes biodegradables para el suministro de insulina por vía oral dirigida al colon activado por la microbiota y proceso para su obtención
CA3154083A1 (en) Methods of promoting scfa production by gut microbiota
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2019011646A (es) Composicion osmoticamente activa para dialisis.
MX2018011685A (es) Proceso para formulaciones solidas de mesalazina.
MX2017007018A (es) Nanopartículas para encapsular compuestos, su preparación y sus usos.
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16876109

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016876109

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016876109

Country of ref document: EP

Effective date: 20180718

122 Ep: pct application non-entry in european phase

Ref document number: 16876109

Country of ref document: EP

Kind code of ref document: A2